r 14

Amchem R 14 is a biochemical.

GSK-3β inhibitor 14 (1,5-Benzothiazepin-4(5H)-one, 2,3-dihydro-2-methyl-5-(phenylmethyl)-) is a weak GSK-3β inhibitor, IC50﹥ 100μM.

Topoisomerase II inhibitor 14 is a potent topoisomerase II inhibitor with anticancer and antioxidant activities.Topoisomerase II inhibitor 14 induces apoptosis and blocks the cell cycle in S phase.Topoisomerase II inhibitor 14 reduces the amount of GSH, MDA and NO. Topoisomerase II inhibitor 14 reduces the amount of GSH, MDA and NO.

Fluprostenol isopropyl ester, a potent agonist of the F-series prostaglandin receptor, serves as a prodrug utilized clinically as an ocular hypotensive agent for glaucoma treatment. An impurity, 13(R),14(R)-epoxy fluprostenol isopropyl ester, arises during its production, existing as a chiral enantiomer of the epoxide. The pharmacological properties of this specific enantiomer have yet to be thoroughly investigated.

KRAS G12C inhibitor 14 is a potent compound with an IC50 of 18 nM [1].

SR 146131 is a potent and selective agonist of the nonpeptide receptor.

WRN inhibitor 14 (compound S35) is an orally administered WRN inhibitor with anticancer properties. It effectively suppresses tumor growth in the SW48 xenograft model in BALB c nude mice.

p53 Activator 14 (Compound 7A) is a derivative of Neratinib that can induce DNA damage and activate p53, thereby inhibiting the proliferation of various cancer cells, with an IC50 of 7.21 μM for HCT116 cells. This compound hinders adhesion, migration, and invasion of HCT116 cells, disrupts the cell cycle, and triggers apoptosis. In addition, p53 Activator 14 exhibits anti-tumor properties and inhibits angiogenesis in the chick embryo chorioallantoic membrane (CAM) model.

SR 142948-C3-NHMe is the methylated form of SR 142948.

Protein kinase inhibitor 14 (Compound 13) exhibits inhibitory effects on various serine threonine kinases and receptor non-receptor tyrosine kinases.

platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist

5-HT6 antagonist,selective and high affinity

SR 140333 is a NK1 receptor antagonist.

SR 142948 is a neurotensin (NT) receptor antagonist.

NK3 receptor antagonist

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM, which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. As a microtubule destabilizer, Tubulin inhibitor 14 has potential tumor-selective, anti-angiogenic, and vascular-destructive properties [1].

Carbonic anhydrase inhibitor 14 (Compound 8b) is a potent CA inhibitor, exhibiting K i values of 1203, 99.7, 9.4, and 27.7 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. Additionally, it effectively inhibits CDK2 with an IC 50 of 20.3 μM and demonstrates significant antitumor activity [1].

KRAS G12D inhibitor 14 is a potent compound that binds the KRAS G12D protein (Kd: 33 nM) and selectively inhibits the active form KRAS G12D-GTP, but not KRAS G13D.

ATX inhibitor 14, an indole-based carbamate derivative, is a potent inhibitor (IC50: 0.41 nM) of self-adhesive proteins (ATX) and has shown potential for research in fibrosis-related diseases.

SR 142948 dihydrochloride is a selective, orally active, non-peptide neurotensin receptor (NT) antagonist, featuring IC50 values of 1.19 nM, 0.32 nM, and 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. It effectively inhibits NT-induced inositol monophosphate formation in HT-29 cells (IC50 = 3.9 nM) and blocks NT-induced hypothermia, analgesia, and steering behavior in vivo. Furthermore, it demonstrates blood-brain barrier permeability, positioning it as a potential tool for psychiatric disorder research [1] [2].

Chitin Synthase Inhibitor 14 (compound 4n), a potent chitin synthase (CHS) inhibitor, exhibits antifungal activity and is effective against drug-resistant fungal strains [1].

Compound (Ra)-10, also known as Mcl-1 inhibitor 14, is a potent inhibitor of myeloid cell leukemia-1 (MCL-1), exhibiting a K_i of 0.018 nM, and holds potential for use in anticancer research [1].

AMPK activator 14 (compound 32), an orally active agent, effectively reduces fasted glucose and insulin levels in a db db mouse model of Type II diabetes [1].

c-Myc Inhibitor 14 (Compound 13A), an inhibitor of the c-Myc protein, exhibits an IC50 value of less than 100 nM in HL60 cells. This compound demonstrates antitumor activity [1].